EGFR and lung adenocarcinoma: Particular interest was shown towards mutations of the epidermal growth factor receptor (EGFR) due to their presence in important proportions of patients with lung adenocarcinomas (up to 50% in Asian populations and 10–35% in Western populations), as well as their ability to predict therapeutic response to EGFR-specific tyrosine kinase inhibitors (TKIs) [2,3,4].